11.14
-0.24(-2.11%)
Currency In USD
Address
500 Technology Square
Boston, MA 02139
United States of America
Phone
617 603 0070
Website
Sector
Healthcare
Industry
Biotechnology
Employees
274
First IPO Date
June 17, 2021
| Name | Title | Pay | Year Born |
| Dr. Sekar Kathiresan M.D. | Co-Founder, Chief Executive Officer & Director | 1.03M | 1973 |
| Dr. Anthony Philippakis M.D., Ph.D. | Co-Founder & Scientific Advisory Board Member | 7,967 | N/A |
| Dr. Burt A. Adelman M.D. | Co-Founder & Independent Chairman of the Board | 100,000 | 1952 |
| Mr. Andrew D. Ashe J.D. | President, Chief Operating Officer & General Counsel | 572,955 | 1967 |
| Ms. Allison Dorval CPA | Chief Financial Officer & Principal Accounting Officer | 690,223 | 1976 |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder | 0 | N/A |
| Dr. Troy Lister Ph.D. | Chief Scientific Officer | 0 | 1980 |
| Dr. Barry S. Ticho FACC, M.D., Ph.D. | Co-Founder | 0 | 1960 |
| Mr. Issi Rozen M.B.A. | Co-Founder & Strategic Advisor | 0 | N/A |
| Dr. Kiran Musunuru M.D., M.P.H., Ph.D. | Co-Founder | 0 | N/A |
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.